Non-Stimulant Comparison

Wellbutrin vs Strattera

A side-by-side look at bupropion and atomoxetine — two non-stimulant, non-controlled options often considered for ADHD and depression.

Wellbutrin
bupropion · NDRI antidepressant
Not controlled Not a stimulant Off-label ADHD
Strattera
atomoxetine · selective NRI
Not controlled Not a stimulant FDA-approved ADHD

Head-to-Head Comparison

Wellbutrin (bupropion)
Strattera (atomoxetine)
Drug class
NDRI — norepinephrine–dopamine reuptake inhibitor
Selective norepinephrine reuptake inhibitor (NRI)
FDA approval
Depression Seasonal AD Smoking cessation
ADHD use is off-label
ADHD (children + adults)
Only medication specifically FDA-approved for ADHD that is non-stimulant & not SNE
Controlled status
Schedule: none
Schedule: none
Onset to full effect
2–4 weeks for mood; variable for ADHD symptoms
4–6 weeks typical; longer than stimulants
Treats depression
✓ FDA-approved for MDD & SAD
✗ Not approved or used for depression
Weight effect
Weight-neutral to modest weight loss
Possible modest weight loss (appetite suppression); may affect growth in children
Sexual side effects
Not associated with sexual dysfunction (unlike SSRIs)
Possible; less studied than SSRIs
Blood pressure
Possible mild increase; monitor
Can increase blood pressure and heart rate; monitor in patients with cardiac history
Seizure risk
Lowers seizure threshold, especially at higher doses; avoid in patients with seizure disorders
Not associated with increased seizure risk
Black box warning
Suicidality in younger patients (shared with all antidepressants)
Suicidality in children/adolescents; also rare hepatotoxicity warning
Smoking cessation
✓ FDA-approved aid to quit smoking (also marketed as Zyban)
✗ Not used for smoking cessation

Available Strengths

Wellbutrin (bupropion)

  • IR tablets — 75 mg · 100 mg
  • SR (sustained-release) — 100 mg · 150 mg · 200 mg
  • XL (extended-release) — 150 mg · 300 mg

Strattera (atomoxetine)

  • Capsules — 10 mg · 18 mg · 25 mg · 40 mg
  • Capsules — 60 mg · 80 mg · 100 mg
  • Generic atomoxetine available in all strengths

When Each May Be Considered

Wellbutrin might be considered when:

A patient has both ADHD symptoms and depression, and the prescriber wants a single agent that may address both. Also a consideration when stimulant medications are not appropriate and depression is the primary diagnosis, or when a patient needs help quitting smoking alongside other concerns.

Its lack of sexual side effects and weight-neutral profile can also be relevant when those are concerns with other antidepressants.

Strattera might be considered when:

A patient needs an FDA-approved ADHD treatment that is non-stimulant and not a controlled substance — for example, in situations where controlled substances are difficult to prescribe, or when there is a history of substance misuse.

Strattera is one of the few non-stimulant ADHD medications specifically approved for adults, making it a distinct option in that population.

Safety Notes

Strattera — Suicidality & Liver Warning. Strattera carries an FDA black box warning for increased suicidal thinking in children and adolescents during early treatment. Patients and caregivers should be aware of behavioral changes. Strattera also carries a warning for rare but serious liver damage; contact a healthcare provider immediately if jaundice or dark urine develops.
Wellbutrin — Seizure Risk. Bupropion lowers the seizure threshold, particularly at higher doses. It should be used with caution or avoided in patients with a history of seizures, eating disorders, or who are abruptly withdrawing from alcohol or benzodiazepines.

Frequently Asked Questions

Neither Wellbutrin (bupropion) nor Strattera (atomoxetine) is a controlled substance. Both are non-stimulant options, which makes them easier to prescribe and refill compared to stimulant ADHD medications like Adderall or Ritalin.

Strattera (atomoxetine) is specifically FDA-approved to treat ADHD in both children and adults. Wellbutrin (bupropion) is not FDA-approved for ADHD — its use in ADHD is off-label. Wellbutrin is FDA-approved for major depressive disorder, seasonal affective disorder, and as an aid to smoking cessation.

Strattera typically takes 4 to 6 weeks to reach its full therapeutic effect. This is longer than stimulant ADHD medications, which can work within hours. Wellbutrin also takes several weeks to reach full effect, consistent with other antidepressants.

Yes. Strattera carries an FDA black box warning for increased risk of suicidal ideation in children and adolescents during early treatment. Patients should be monitored closely, particularly at the start of therapy. Strattera also carries a warning for rare but serious hepatotoxicity (liver damage).

Wellbutrin is FDA-approved for depression and is commonly used off-label for ADHD, so it may be a consideration when a patient has both conditions. However, treatment decisions should always be made by a licensed healthcare provider based on an individual's full clinical picture.

Wellbutrin IR tablets: 75 mg and 100 mg. Wellbutrin SR (sustained-release): 100 mg, 150 mg, and 200 mg. Wellbutrin XL (extended-release): 150 mg and 300 mg. Generic bupropion is widely available in these same strengths.

Strattera (atomoxetine) capsules are available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg. Generic atomoxetine is available in the same strengths.

Unlike many SSRIs, Wellbutrin (bupropion) is weight-neutral or associated with modest weight loss in some patients, and it is not associated with the sexual side effects common to SSRIs. This can make it a preferred choice for patients concerned about those effects from other antidepressants.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice. Drug information may change over time. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. PillID / QuickPillID does not endorse any specific treatment.